Authors
Na Wang, Kai Wang, Huawen Han, Jingwen Fan, Feixue Song, Hao Chen, Xiangkai Li
Published in
Frontiers in immunology. Volume 17. Pages 1987320. Epub Oct 29, 2026.
Abstract
To investigate whether the Jiangshui-derived probiotic Lactobacillus plantarum GR-4 can enhance gastric cancer sensitivity to PD-1 inhibitors and reshape the tumor immune microenvironment.
A mouse gastric cancer model was established. Mice received oral GR-4 monotherapy, PD-1 blocking antibody monotherapy, or combined GR-4 and PD-1 antibody treatment. In vivo antitumor efficacy was evaluated by measuring tumor weight. We assessed CD8+ T-cell infiltration, cytokines related to T-cell activation and differentiation, and the expression of the activation marker CD69 on CD3+/CD8+ T cells within tumor tissues. 16S rRNA sequencing of gut microbiota and fecal metabolomic analysis were performed to explore the regulatory effects of GR-4 on gut microbiota composition and metabolic profiles. In vitro, human gastric cancer BGC-823 cells were treated with GR-4 combined with PD-1 intervention, and transcriptome sequencing was applied to further validate the underlying molecular regulatory mechanisms.
In vivo results demonstrated that combined GR-4 and PD-1 antibody treatment exerted prominent synergistic antitumor activity, effectively suppressing tumor growth while markedly mitigating PD-1-associated body weight loss (p < 0.01). Further assays revealed that GR-4 synergistically elevated tumor-infiltrating CD3+/CD8+ T-cell levels and upregulated CD69 expression on these cells, thereby remodelling the tumor immune microenvironment. Additionally, GR-4, whether administered alone or combined with PD-1 antibody, optimized gut microbiota structure, increased the abundance of probiotic genera including Ligilactobacillus and Bacteroides, reversed intestinal metabolic disturbances, and raised the levels of short-chain fatty-acid-related metabolites such as ethoxyacetic acid and 2,5-dihydroxybenzoic acid. Transcriptomic sequencing showed significant enrichment of the PD-1 checkpoint pathway in the GR-4 group versus Ctrl (p=0.01), whereas no significant enrichment was observed between the PD-1 inhibitor group and GR-4/PD-1 inhibitor group (p=0.14).
This study is the first to confirm that Lactobacillus plantarum GR-4 synergizes with PD-1 inhibitors to restrain gastric cancer progression via T-cell activation and elevated intratumoral T-cell infiltration. These findings provide novel theoretical evidence and a potential combinatorial immunotherapeutic strategy for gastric cancer.
PMID:
43022041
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0